Insider Selling: Palomar (NASDAQ:PLMR) CFO Sells $101,042.34 in Stock

Palomar Holdings, Inc. (NASDAQ:PLMR) CFO T Christopher Uchida sold 791 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $127.74, for a total transaction of $101,042.34. Following the completion of the transaction, the chief financial officer directly owned 16,238 shares in the company, valued at approximately $2,074,242.12. The trade was a 4.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Palomar Stock Performance

Shares of NASDAQ PLMR opened at $130.09 on Friday. Palomar Holdings, Inc. has a 12-month low of $100.81 and a 12-month high of $147.62. The firm has a market capitalization of $3.42 billion, a price-to-earnings ratio of 17.49 and a beta of 0.40. The company has a current ratio of 0.50, a quick ratio of 0.50 and a debt-to-equity ratio of 0.30. The firm has a 50 day moving average of $130.76 and a 200 day moving average of $123.92.

Palomar (NASDAQ:PLMR) last released its quarterly earnings results on Tuesday, August 4th. The company reported $2.36 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.17. Palomar had a net margin of 18.61% and a return on equity of 23.28%. The business had revenue of $314.42 million for the quarter, compared to the consensus estimate of $621.52 million. During the same period last year, the firm earned $1.76 earnings per share. On average, research analysts anticipate that Palomar Holdings, Inc. will post 9.21 earnings per share for the current year.

Palomar Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 2nd. Investors of record on Wednesday, August 19th will be given a dividend of $0.45 per share. The ex-dividend date is Wednesday, August 19th. This represents a $1.80 annualized dividend and a yield of 1.4%. Palomar’s payout ratio is 24.19%.

Analyst Upgrades and Downgrades

PLMR has been the subject of a number of analyst reports. Keefe, Bruyette & Woods upped their price target on Palomar from $166.00 to $167.00 and gave the stock an “outperform” rating in a research report on Monday, August 10th. Evercore set a $152.00 price objective on Palomar in a research report on Friday, July 10th. Weiss Ratings upgraded Palomar from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 18th. Zacks Research lowered shares of Palomar from a “strong-buy” rating to a “hold” rating in a report on Friday, May 15th. Finally, Piper Sandler lifted their price target on shares of Palomar from $132.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Palomar has an average rating of “Moderate Buy” and a consensus price target of $162.75.

Institutional Trading of Palomar

Several institutional investors have recently made changes to their positions in the business. Geneos Wealth Management Inc. purchased a new stake in Palomar during the 4th quarter valued at approximately $32,000. Kestra Advisory Services LLC purchased a new position in shares of Palomar in the fourth quarter worth $33,000. Rockefeller Capital Management L.P. boosted its position in shares of Palomar by 81.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 294 shares of the company’s stock worth $40,000 after acquiring an additional 132 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Palomar during the second quarter worth $43,000. Finally, Frazier Financial Advisors LLC purchased a new position in Palomar during the second quarter valued at $51,000. Hedge funds and other institutional investors own 90.25% of the company’s stock.

Key Palomar News

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Strong premium growth and expansion in specialty insurance are expected to support Palomar’s earnings momentum. Analysts’ average price target of $162.75 and recent target increases reinforce the bullish view. Can Strong Premium Growth Sustain Palomar’s Earnings Momentum?
• Positive Sentiment: Dowling & Partners expressed a positive view of Palomar’s fiscal 2026 earnings outlook, adding to expectations for continued profit growth. DOWLING & PARTN Has Positive View of Palomar FY2026 Earnings
• Positive Sentiment: Palomar’s latest quarterly results provide fundamental support: earnings per share of $2.36 exceeded the $2.19 consensus estimate, while profitability and return on equity remained strong.
• Neutral Sentiment: Several insiders, including the president, CFO and Jonathan Knutzen, sold relatively small portions of their holdings to cover tax withholding on vested equity awards. Because the transactions were not discretionary sales, they are less negative than typical insider selling, though they may limit near-term sentiment.
• Neutral Sentiment: Palomar declared a quarterly dividend of $0.45, equivalent to $1.80 annually and a yield of approximately 1.4%, providing modest shareholder support.
• Negative Sentiment: Competitive pricing could reduce premium profitability, while a higher combined ratio would pressure underwriting margins. These risks may temper the market’s response to otherwise strong growth expectations. Can Strong Premium Growth Sustain Palomar’s Earnings Momentum?

Palomar Company Profile

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.